Pfizer Release - Search News

Pfizer, Novo Nordisk and Metsera

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an amended acquisition proposal to Metsera for $62.20 per share, a total value of $7.2 billion. Shortly after receiving the amended proposal, Metsera’s board of directors suggested to stockholders to approved Pfizer’s acquisition. 3

· 3h

Metsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer

Becker's Hospital Review · 12d

Pfizer says Novo Nordisk’s Metsera bid breaks law

Zacks Investment Research on MSN

Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B

The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity ...

7don MSN

Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute

Pfizer (PFE) is set to report its Q3 earnings on Tuesday, November 4, before the market opens. Wall Street expects earnings ...

23h

Pfizer shows hardball mettle needed to win in 2025 M&A

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results